Expression and prognostic significance of CIP2A mRNA in hepatocellular carcinoma and nontumoral liver tissues

Biomarkers

Volumn 17, Issue 5, 2012, Pages 422-429

  Huang, Pinzhu ^a   Qiu, Jiliang ^a   You, Jinghong ^b   Hong, Jian ^a   Li, Binkui ^a   Zhou, Kai ^b   Chen, Guihua ^c   Yuan, Yunfei ^a   Zou, Ruhai ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b People's Hospital of Jiangxi Province   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cancerous inhibitor of protein phosphatase 2A (CIP2A); Hepatocellular carcinoma; MRNA expression; Prognosis

Indexed keywords

CANCEROUS INHIBITOR OF PROTEIN PHOSPHATASE 2A; MESSENGER RNA; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENCAPSULATION; FEMALE; HUMAN; LIVER; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER RESECTION; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION;

AUTOANTIGENS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER; LIVER NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84864581244     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.680608     Document Type: Article

References (32)

1. Agrawal S, Belghiti J. (2011). Oncologic resection for malignant tumors of the liver. Ann Surg 253:656-665.
2. Aravalli RN, Steer CJ, Cressman EN. (2008). Molecular mechanisms of hepatocellular carcinoma. Hepatology 48:2047-2063.
3. Bkelman C, Hagstr J, Minen LK, Keski-Stti H, Hry V, Lundin J, Atula T, Ristimi A, Haglund C. (2011). High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer. Br J Cancer 104:1890-1895.
4. Bruix J, Llovet JM. (2009). Major achievements in hepatocellular carcinoma. Lancet 373:614-616.
5. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY, Wang XW. (2006). Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10:99-111.
6. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL. (2010a). CIP2A mediates effects of bortezomib on phospho- Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 29:6257-6266.
7. Chen KF, Yu HC, Liu TH, Lee SS, Chen PJ, Cheng AL. (2010b). Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation. J Hepatol 52:88-95.
8. Ce C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thenas S, Westermarck J. (2009). CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res 15:5092-5100.
9. Cristal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. (2011). PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 25:606-614.
10. Dong QZ, Wang Y, Dong XJ, Li ZX, Tang ZP, Cui QZ, Wang EH. (2011). CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis. Ann Surg Oncol 18:857-865.
11. El-Serag HB, Rudolph KL. (2007). Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576.
12. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. (2008). Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359:1995-2004.
13. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. (2011). Global cancer statistics. CA Cancer J Clin 61:69-90.
14. Junttila MR, Puustinen P, NiemelM, Ahola R, Arnold H, Btzauw T, Ala-Aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grman R, Kast J, Kallunki T, Sears R, Ki VM, Westermarck J. (2007). CIP2A inhibits PP2A in human malignancies. Cell 130:51-62.
15. Katz J, Jakymiw A, Ducksworth MK, Stewart CM, Bhattacharyya I, Cha S, Chan EK. (2010). CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biol Ther 0:694-699.
16. Kerosuo L, Fox H, PerN, Ahlqvist K, Suomalainen A, Westermarck J, Sariola H, Wartiovaara K. (2010). CIP2A increases self-renewal and is linked to Myc in neural progenitor cells. Differentiation 80:68-77.
17. Khanna A, Bkelman C, Hemmes A, Junttila MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C, Westermarck J, Ristimi A. (2009). MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. J Natl Cancer Inst 101:793-805.
18. Li W, Ge Z, Liu C, Liu Z, Bjkholm M, Jia J, Xu D. (2008). CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells. Clin Cancer Res 14:3722-3728.
19. Libbrecht L, Craninx M, Nevens F, Desmet V, Roskams T. (2001). Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 39:66-73.
20. Liu J, Wang X, Zhou G, Wang H, Xiang L, Cheng Y, Liu W, Wang Y, Jia J, Zhao W. (2011). Cancerous inhibitor of protein phosphatase 2A is overexpressed in cervical cancer and upregulated by human papillomavirus 16 E7 oncoprotein. Gynecol Oncol 122:430-436.
21. Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. (2011). Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood 117:6660-6668.
22. Morimoto O, Nagano H, Sakon M, Fujiwara Y, Yamada T, Nakagawa H, Miyamoto A, Kondo M, Arai I, Yamamoto T, Ota H, Dono K, Umeshita K, Nakamori S, Sasaki Y, shikawa O, Imaoka S, Monden M. (2003). Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas. J Hepatol 39:215-221.
23. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. (2000). Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 89:500-507.
24. Qiu J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y. (2011) Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med 9:166.
25. Qu W, Li W, Wei L, Xing L, Wang X, Yu J. (2012). CIP2A is overexpressed in esophageal squamous cell carcinoma. Med Oncol 29:113-118.
26. Rahbari NN, Mehrabi A, Mollberg NM, Mler SA, Koch M, Bhler MW, Weitz J. (2011). Hepatocellular carcinoma: Current management and perspectives for the future. Ann Surg 253:453-469.
27. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. (2008). Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: A systematic review and meta-Analysis. Gut 57:1592-1596.
28. Vaarala MH, Vsen MR, Ristimi A. (2010). CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 29:136.
29. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM. (2010a). New strategies in hepatocellular carcinoma: Genomic prognostic arkers. Clin Cancer Res 16:4688-4694.
30. Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. (2010b). Hepatocellular carcinoma: Novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61:317-328.
31. Wang J, Li W, Li L, Yu X, Jia J, Chen C. (2011). CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 33:290-298.
32. Xu HX, Zhu XD, Zhuang PY, Zhang JB, Zhang W, Kong LQ, Wang WQ, Liang Y, Wu WZ, Wang L, Fan J, Tang ZY, Sun HC. (2011). Expression and prognostic significance of placental growth factor in hepatocellular carcinoma and peritumoral liver tissue. Int J Cancer 128:1559-1569.